...
首页> 外文期刊>Annals of Internal Medicine >Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study
【24h】

Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study

机译:艾滋病毒和丙型肝炎病毒合并感染的抗逆转录病毒治疗患者与丙型肝炎病毒单一感染患者的肝脏代偿失调:一项队列研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The incidence and determinants of hepatic decompensation have been incompletely examined among patients coinfected with HIV and hepatitis C virus (HCV) in the antiretroviral therapy (ART) era, and few studies have compared outcome rates with those of patients with chronic HCV alone. Objective: To compare the incidence of hepatic decompensation between antiretroviral- treated patients co-infected with HIV and HCV and HCV-monoinfected patients and to evaluate factors associated with decompensation among co-infected patients receiving ART. Design: Retrospective cohort study. Setting: Veterans Health Administration. Patients: 4280 co-infected patients who initiated ART and 6079 HCV-monoinfected patients receiving care between 1997 and 2010. All patients had detectable HCV RNA and were HCV treatment-naive. Measurements: Incident hepatic decompensation, determined by diagnoses of ascites, spontaneous bacterial peritonitis, or esophageal variceal hemorrhage. Results: The incidence of hepatic decompensation was greater among co-infected than monoinfected patients (7.4% vs. 4.8% at 10 years; P < 0.001). Compared with HCV-monoinfected patients, co-infected patients had a higher rate of hepatic decompensation (hazard ratio [HR] accounting for competing risks, 1.56 [95% CI, 1.31 to 1.86]). Co-infected patients who maintained HIV RNA levels less than 1000 copies/mL still had higher rates of decompensation than HCV-monoinfected patients (HR, 1.44 [CI, 1.05 to 1.99]). Baseline advanced hepatic fibrosis (FIB-4 score >3.25) (HR, 5.45 [CI, 3.79 to 7.84]), baseline hemoglobin level less than 100 g/L (HR, 2.24 [CI, 1.20 to 4.20]), diabetes mellitus (HR, 1.88 [CI, 1.38 to 2.56]), and nonblack race (HR, 2.12 [CI, 1.65 to 2.72]) were each associated with higher rates of decompensation among co-infected patients. Limitation: Observational study of predominantly male patients. Conclusion: Despite receiving ART, patients co-infected with HIV and HCV had higher rates of hepatic decompensation than HCVmonoinfected patients. Rates of decompensation were higher for co-infected patients with advanced liver fibrosis, severe anemia, diabetes, and nonblack race. Primary Funding Source: National Institutes of Health.
机译:背景:在抗逆转录病毒疗法(ART)时代,在HIV和丙型肝炎病毒(HCV)合并感染的患者中,肝代偿失调的发生率和决定因素尚未得到全面检查,很少有研究将结局发生率与单纯慢性HCV患者的发生率进行比较。目的:比较抗逆转录病毒治疗的合并感染HIV和HCV的患者与HCV单一感染的患者之间肝脏代偿失调的发生率,并评估与ART合并感染的患者中代偿失调的相关因素。设计:回顾性队列研究。地点:退伍军人卫生管理局。患者:1997年至2010年之间,有4280例开始接受抗逆转录病毒治疗的并发感染患者和6079例被HCV感染的患者接受了治疗。所有患者均具有可检测的HCV RNA,且未接受过HCV治疗。措施:突发性肝失代偿,通过诊断为腹水,自发性细菌性腹膜炎或食管静脉曲张破裂出血来确定。结果:合并感染的患者肝失代偿的发生率高于单一感染的患者(10年时分别为7.4%和4.8%; P <0.001)。与HCV单一感染患者相比,合并感染患者的肝失代偿率更高(危险比[HR]占竞争风险,1.56 [95%CI,1.31至1.86])。 HIV RNA水平低于1000拷贝/ mL的合并感染患者的失代偿率仍高于HCV单感染患者(HR,1.44 [CI,1.05至1.99])。基线晚期肝纤维化(FIB-4评分> 3.25)(HR,5.45 [CI,3.79至7.84]),基线血红蛋白水平低于100 g / L(HR,2.24 [CI,1.20至4.20]),糖尿病( HR,1.88 [CI,1.38至2.56])和非黑人种族(HR,2.12 [CI,1.65至2.72])均与合并感染患者中较高的失代偿率相关。局限性:主要是男性患者的观察性研究。结论:尽管接受抗逆转录病毒治疗,但同时感染HIV和HCV的患者的肝失代偿率要高于HCV单感染的患者。合并感染的晚期肝纤维化,严重贫血,糖尿病和非黑人种族患者的失代偿率更高。主要资金来源:美国国立卫生研究院。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号